Current Liabilities
Accounts payable and other current liabilities (Note 11)
AbbVie Accounts payable and other current liabilities (Note 11) decreased by 2.8% to $33.77B in Q1 2026 compared to the prior quarter.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ4 2015
Last reportedQ1 2026
How to read this metric
An increase can signal improved cash management (extending payment terms) or higher operational activity, while a decrease may indicate faster payments to suppliers.
Detailed definition
This represents short-term obligations to suppliers for goods and services received, along with other accrued expenses....
Peer comparison
Standard metric for assessing working capital efficiency and trade credit usage across all industries.
Metric ID:
current_liabilities_accounts_payable_and_accrued_liabili_26f6ceHistorical Data
2 periods
| Q4 '25 | Q1 '26 | |
|---|---|---|
| Value | $34.73B | $33.77B |
| QoQ Change | — | -2.8% |
Range$33.77B – $34.73B
Accounts payable and other current liabilities (Note 11) at Other Companies
Frequently Asked Questions
- What is AbbVie's accounts payable and other current liabilities (note 11)?
- AbbVie (ABBV) reported accounts payable and other current liabilities (note 11) of $33.77B in Q1 2026.
- What does accounts payable and other current liabilities (note 11) mean?
- Short-term debts owed to suppliers and other accrued operational expenses.